Its relevance during GLP-1 therapy is limited to general oxidative-stress support during caloric deficit not to amplifying or replacing medication effects
In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes related patent portfolios of Helmholtz Zentrum Mnchen as, for example, WO/2016/188932 A2 or WO/2017/194499 A1
Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE).10,33 With regard to the secondary outcome of HF hospitalisation, the results were neutral, with LEADER showing a non-significant relative risk reduction (RRR) of 13% with liraglutide compared with placebo and SUSTAIN-6 showing no significant difference between the semaglutide and placebo treatment groups.10,33 Similarly, the REWIND trial, in patients with T2D and established CVD or cardiovascular risk factors, reported that dulaglutide significantly reduced the incidence of MACE (primary outcome)
Common wegovy side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, constipation, and abdominal pain
It uses the same active ingredient as Ozempic and Wegovy, often at a lower cost and with the ability to tailor doses to patient needs
As depicted in our graphical abstract (Supplementary Fig
